969 related articles for article (PubMed ID: 33562193)
41. The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection.
Maiuolo J; Mollace R; Gliozzi M; Musolino V; Carresi C; Paone S; Scicchitano M; Macrì R; Nucera S; Bosco F; Scarano F; Zito MC; Ruga S; Tavernese A; Mollace V
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291346
[TBL] [Abstract][Full Text] [Related]
42. Cardiovascular Manifestations of COVID-19 Infection.
Magadum A; Kishore R
Cells; 2020 Nov; 9(11):. PubMed ID: 33228225
[TBL] [Abstract][Full Text] [Related]
43. Cardiac Involvement of COVID-19: A Comprehensive Review.
Chang WT; Toh HS; Liao CT; Yu WL
Am J Med Sci; 2021 Jan; 361(1):14-22. PubMed ID: 33187633
[TBL] [Abstract][Full Text] [Related]
44. Mechanisms of COVID-19-induced cardiovascular disease: Is sepsis or exosome the missing link?
Patil M; Singh S; Henderson J; Krishnamurthy P
J Cell Physiol; 2021 May; 236(5):3366-3382. PubMed ID: 33078408
[TBL] [Abstract][Full Text] [Related]
45. Tryptophan Metabolites and Aryl Hydrocarbon Receptor in Severe Acute Respiratory Syndrome, Coronavirus-2 (SARS-CoV-2) Pathophysiology.
Anderson G; Carbone A; Mazzoccoli G
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562472
[TBL] [Abstract][Full Text] [Related]
46. Jeopardy of COVID-19: Rechecking the Perks of Phytotherapeutic Interventions.
Saha P; Bose S; Srivastava AK; Chaudhary AA; Lall R; Prasad S
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833873
[TBL] [Abstract][Full Text] [Related]
47. Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management.
Deidda S; Tora L; Firinu D; Del Giacco S; Campagna M; Meloni F; Orrù G; Chessa L; Carta MG; Melis A; Spolverato G; Littera R; Perra A; Onali S; Zorcolo L; Restivo A
Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):41-50. PubMed ID: 32955375
[TBL] [Abstract][Full Text] [Related]
48. COVID-19 and cardiovascular disease.
Guijarro C
Clin Investig Arterioscler; 2020; 32(6):263-266. PubMed ID: 33213825
[No Abstract] [Full Text] [Related]
49. Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry.
Gómez-Mesa JE; Galindo-Coral S; Montes MC; Alarco W; Barisani JL; Magaña A; Perna ER; Romero A; Speranza M; Mendoza I; Wyss F
Glob Heart; 2021 Feb; 16(1):14. PubMed ID: 33833938
[TBL] [Abstract][Full Text] [Related]
50. The Contribution of Biophysics and Structural Biology to Current Advances in COVID-19.
Barrantes FJ
Annu Rev Biophys; 2021 May; 50():493-523. PubMed ID: 33957057
[TBL] [Abstract][Full Text] [Related]
51. Acute Cardiac Injury in Coronavirus Disease 2019 and Other Viral Infections-A Systematic Review and Meta-Analysis.
Cheng MP; Cau A; Lee TC; Brodie D; Slutsky A; Marshall J; Murthy S; Lee T; Singer J; Demir KK; Boyd J; Ohm H; Maslove D; Goffi A; Bogoch II; Sweet DD; Walley KR; Russell JA;
Crit Care Med; 2021 Sep; 49(9):1558-1566. PubMed ID: 33870918
[TBL] [Abstract][Full Text] [Related]
52. Long-term effect of SARS-CoV-2 infection on cardiovascular outcomes and all-cause mortality.
Aleksova A; Fluca AL; Gagno G; Pierri A; Padoan L; Derin A; Moretti R; Noveska EA; Azzalini E; D'Errico S; Beltrami AP; Zumla A; Ippolito G; Sinagra G; Janjusevic M
Life Sci; 2022 Dec; 310():121018. PubMed ID: 36183780
[TBL] [Abstract][Full Text] [Related]
53. COVID-19 infection and stroke risk.
Sadeghmousavi S; Rezaei N
Rev Neurosci; 2021 Apr; 32(3):341-349. PubMed ID: 33580645
[TBL] [Abstract][Full Text] [Related]
54. Cardiovascular disturbances in COVID-19: an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2.
Lawal IO; Kgatle MM; Mokoala K; Farate A; Sathekge MM
BMC Cardiovasc Disord; 2022 Mar; 22(1):93. PubMed ID: 35264107
[TBL] [Abstract][Full Text] [Related]
55. SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
Ogah OS; Umuerri EM; Adebiyi A; Orimolade OA; Sani MU; Ojji DB; Mbakwem AC; Stewart S; Sliwa K
Glob Heart; 2021 Mar; 16(1):18. PubMed ID: 33833942
[TBL] [Abstract][Full Text] [Related]
56. The effects of novel coronavirus (SARS-CoV-2) infection on cardiovascular diseases and cardiopulmonary injuries.
Li N; Zhu L; Sun L; Shao G
Stem Cell Res; 2021 Mar; 51():102168. PubMed ID: 33485182
[TBL] [Abstract][Full Text] [Related]
57. Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications.
Higashikuni Y; Liu W; Obana T; Sata M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769508
[TBL] [Abstract][Full Text] [Related]
58. COVID-19 patients may become predisposed to pulmonary arterial hypertension.
Suzuki YJ; Nikolaienko SI; Shults NV; Gychka SG
Med Hypotheses; 2021 Feb; 147():110483. PubMed ID: 33444904
[TBL] [Abstract][Full Text] [Related]
59. Cardiovascular Manifestations and Mechanisms in Patients with COVID-19.
Dou Q; Wei X; Zhou K; Yang S; Jia P
Trends Endocrinol Metab; 2020 Dec; 31(12):893-904. PubMed ID: 33172748
[TBL] [Abstract][Full Text] [Related]
60. Pathomechanisms of SARS-CoV-2 infection and development of atherosclerosis in patients with COVID-19: A review.
Gospodarczyk AZ; Wojciechowska C; Marczewski KP; Gospodarczyk NJ; Zalejska-Fiolka J
Medicine (Baltimore); 2022 Dec; 101(49):e31540. PubMed ID: 36626452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
